Anteris Technologies Glob... (AVR)
| Bid | 2.81 |
| Market Cap | 110.34M |
| Revenue (ttm) | 2.7M |
| Net Income (ttm) | -76.29M |
| EPS (ttm) | -1.98 |
| PE Ratio (ttm) | -1.55 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.07 |
| Volume | 403,154 |
| Avg. Volume (20D) | 212,627 |
| Open | 2.60 |
| Previous Close | 2.58 |
| Day's Range | 2.60 - 3.08 |
| 52-Week Range | 2.34 - 8.79 |
| Beta | 0.47 |
About AVR
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcifica...
Analyst Forecast
According to 4 analyst ratings, the average rating for AVR stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 470.03% from the latest price.
Stock Forecasts
4 months ago · https://www.proactiveinvestors.com
Anteris Technologies prepares for US initial public offering with Registration StatementAnteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has filed a Registration Statement on Form S-1 with the US Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) of Anteri...